• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests

tetano

Editor, Senior Moderator
Sci Rep


. 2022 Mar 1;12(1):3351.
doi: 10.1038/s41598-022-07263-8.
SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests


Grant A Kay[SUP] 1 2 [/SUP], Sophie I Owen[SUP] 1 [/SUP], Emanuele Giorgi[SUP] 3 [/SUP], David J Clark[SUP] 4 [/SUP], Christopher T Williams[SUP] 1 [/SUP], Stefanie Menzies[SUP] 1 [/SUP], Luis E Cuevas[SUP] 1 [/SUP], Benedict M O Davies[SUP] 4 [/SUP], Nicholas M Eckersley[SUP] 4 [/SUP], Grant L Hughes[SUP] 2 [/SUP], Daniela E Kirwan[SUP] 4 [/SUP], Sanjeev Krishna[SUP] 4 5 6 7 [/SUP], Edward I Patterson[SUP] 2 8 [/SUP], Tim Planche[SUP] 4 5 [/SUP], Henry M Staines[SUP] 9 [/SUP], Emily R Adams[SUP] 10 [/SUP]



Affiliations

Abstract

Severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread globally since its emergence in 2019. Most SARS-CoV-2 infections generate immune responses leading to rising levels of immunoglobulins (Ig) M, A and G which can be detected using diagnostic tests including enzyme-linked immunosorbent assays (ELISA). Whilst implying previous SARS-CoV-2 infection, the detection of Ig by ELISA does not guarantee the presence of neutralising antibodies (NAb) that can prevent the virus infecting cells. Plaque reduction neutralisation tests (PRNT) detect NAb, but are not amenable to mass testing as they take several days and require use of SARS-CoV-2 in high biocontainment laboratories. We evaluated the ability of IgG and IgM ELISAs targeting SARS-CoV-2 spike subunit 1 receptor binding domain (S1-RBD), and spike subunit 2 (S2) and nucleocapsid protein (NP), at predicting the presence and magnitude of NAb determined by PRNT. IgG S2 + NP ELISA was 96.8% [95% CI 83.8-99.9] sensitive and 88.9% [95% CI 51.8-99.7] specific at predicting the presence of NAbs (PRNT[SUB]80[/SUB] > 1:40). IgG and IgM S1-RBD ELISAs correlated with PRNT titre, with higher ELISA results increasing the likelihood of a robust neutralising response. The IgM S1-RBD assay can be used as a rapid, high throughput test to approximate the magnitude of NAb titre.
 
Back
Top Bottom